Search results for "live"

showing 10 items of 5911 documents

Chronic Intermittent Hypoxia is associated with Liver Damage and Atherosclerosis in Patients with Non-alcoholic Fatty Liver Disease

2015

medicine.medical_specialtyHepatologybusiness.industryFatty liverGastroenterologyNon alcoholicDiseasemedicine.diseaseGastroenterologyInternal medicinemedicineChronic intermittent hypoxiaIn patientLiver damagebusinessDigestive and Liver Disease
researchProduct

Hyperuricemia in non-alcoholic fatty liver disease: authors’ reply

2011

medicine.medical_specialtyHepatologybusiness.industryFatty liverGastroenterologyNon alcoholicDiseasemedicine.diseaseGastroenterologyInternal medicinemedicinePharmacology (medical)HyperuricemiabusinessAlimentary Pharmacology & Therapeutics
researchProduct

Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease

2011

SUMMARY Background Hyperuricemia has been associated with metabolic disorders. In this line recent studies observed an independent link between higher uric acid serum levels and clinical diagnosis of non-alcoholic fatty liver disease (NAFLD). Mean uric acid serum level was 5.75 mg ⁄ dL, and about 20% of patients had hyperuricemia, that was independently associated with younger age (OR 0.951, 95% CI 0.918-0.984, P = 0.004), lobular inflammation (OR 2.144, 95% CI 1.055-4.357, P = 0.03) and steatosis grade (OR 1.859, 95% CI 1.078-3.205, P = 0.02), by multivariate logistic regression analysis. Female gender (OR 2.656, 95% CI 1.190-5.928, P = 0.01), higher HOMA index (OR 1.219, 95% CI 1.043- 1.4…

medicine.medical_specialtyHepatologybusiness.industryFatty liverGastroenterologyNon alcoholicDiseasemedicine.diseaseLogistic regressionGastroenterologyEndocrinologyInternal medicineMedicinePharmacology (medical)In patientHyperuricemiaLiver damageSteatosisbusinessAlimentary Pharmacology & Therapeutics
researchProduct

P1013 : Chronic intermittent hypoxia is associated with liver damage and atherosclerosis in patients with non-alcoholic fatty liver disease

2015

all the steatosis grades, except S2 vs S3. The diagnostic performances of CAP in quantifying each steatosis grade was: for S ≥1 AUC=0.813 (cutoff 260dB/m, Se = 64.84%, Sp =87.27%, PPV=80.8%, NPV=75%, +LR =5.09, −LR =0.40, DA=76.11%); for S ≥2 AUC=0.822 (cutoff 285dB/m, Se = 69.70%, Sp =85.12%, PPV=47.9%, NPV=93.5%, +LR =4.68, −LR =0.36, DA=82.08%); for S ≥3 AUC=0.838 (cutoff 294dB/m, Se =83.33%, Sp =82.54%, PPV=23.3%, NPV=98.7%, +LR =4.77, −LR =0.20, DA=81.59%). AUCs calculated between two steatosis grades only were: 0.772 (for S0 vs S1), 0.874 (S0 vs S2), 0.904 (S0 vs S3), 0.659 (S1 vs S2), 0.777 (S1 vs S3), and 0.665 (S2 vs S3) respectively. Conclusions: Maximal diagnostic accuracy could …

medicine.medical_specialtyHepatologybusiness.industryFatty liverNon alcoholicDiseasemedicine.diseaseGastroenterologyInternal medicinemedicineCutoffChronic intermittent hypoxiaIn patientLiver damageSteatosisbusinessJournal of Hepatology
researchProduct

Letter: coronary atherosclerosis in patients with significant hepatic fibrosis in non‐alcoholic fatty liver disease—the role for non‐invasive testing

2021

medicine.medical_specialtyHepatologybusiness.industryFatty liverNon invasiveGastroenterologyNon alcoholicDiseasemedicine.diseaseGastroenterologyText miningInternal medicinemedicinePharmacology (medical)In patientbusinessHepatic fibrosisCoronary atherosclerosisAlimentary Pharmacology & Therapeutics
researchProduct

Assessment by Fibroscan of fibrosis in nonalcoholic fatty liver disease: XL versus M probe?

2012

--

medicine.medical_specialtyHepatologybusiness.industryFibrosisInternal medicineNAFLD FIBROSIS FIBROSCANNonalcoholic fatty liver diseasemedicinemedicine.diseasebusinessGastroenterologyLiver pathologyHepatology
researchProduct

Screening for celiac disease in patients with chronic liver disease

2003

Dear Sir:We read with interest the paper of Kaukinen et al. reporting anelevated frequency of celiac disease (CD) (4.3%) in patients with previousliver transplantation due to severe hepatic dysfunction.1However, wewould like to report our experience of the serologic assays for CDdiagnosis in patients with chronic liver disease and comment on thescreening methods for CD used in that study. Between January andOctober 2001, we studied 96 consecutive subjects (65 male, 31 female,age range 18–87 years, median 42) with chronic hypertransaminasemiawho were attending for thefirst time the outpatients clinic for liverdisease at the Internal Medicine Division of the University Hospital ofPalermo. All…

medicine.medical_specialtyHepatologybusiness.industryGastroenterologyMEDLINEDiseaseChronic liver diseasemedicine.diseaseGastroenterologyChronic diseaseInternal medicinemedicineScreening celiac disease chronic liver diseaseIn patientbusiness
researchProduct

FNDC5 rs3480 A>G polymorphism disentangles steatosis from fibrosis severity in patients with nonalcoholic fatty liver disease

2016

S. Petta1, L. Valenti2, R.M. Pipitone1, P. Dongiovanni2, C. Camma1, A.L. Fracanzani2, V. Di Marco1, M. Milano2, S. Grimaudo1, S. Fargion2, A. Craxi1 1 Section of Gastroenterology, Di.Bi.M.I.S., University of Palermo, Palermo, Italy 2 Department of Pathophysiology and Transplantation, Universita degli Studi, Internal Medicine, Fondazione Ca’ Granda IRCCS Ospedale Maggiore Policlinico, Milano, Italy

medicine.medical_specialtyHepatologybusiness.industryGastroenterologymedicine.diseaseGastroenterologyFNDC5TransplantationFibrosisInternal medicineNonalcoholic fatty liver diseaseMedicineIn patientSteatosisbusinessDigestive and Liver Disease
researchProduct

Functional gastrointestinal disorders: Dynamic observation of pediatric cases

2015

Introduction: Functional gastrointestinal disorders (FGID) are a variable set of clinical cases characterized by recurrent/chronic symptoms not associated with an organic pathology. These disorders are classified using the Rome III criteria. Objective: The study wanted to evaluate the prevalence by gender and age of FGIDs in a pediatric population recruited on the basis of recurrent/chronic abdominal pain, and to follow up patients for six months by administering questionnaires aimed at verifying any changes in symptoms. We also evaluated the possible involvement of factors responsible for these changes. Results: 62 patients between 4 and 17 years of age (27 males and 35 females) were inclu…

medicine.medical_specialtyHepatologybusiness.industryGastroenterologymedicine.diseaseGastroenterologyIntestinal motilityLiver diseaseSettore MED/38 - Pediatria Generale E SpecialisticaInternal medicineFGIDmedicineAnal sphincterbusinessDigestive and Liver Disease
researchProduct

Letter: liver dysfunction and survival in hepatocellular carcinoma treated by transarterial chemoembolisation - authors’ reply

2012

medicine.medical_specialtyHepatologybusiness.industryGeneral surgeryGastroenterologymedicine.diseaseGastroenterologyInternal medicineHepatocellular carcinomahepatocellular carcinoma transarterial chemoembolisationmedicinePharmacology (medical)Liver dysfunctionbusinessAlimentary Pharmacology & Therapeutics
researchProduct